What Investor's Are Expecting Ahead of Multiple Nektar Therapeutics Catalysts
Nektar Therapeutics is a biotech company that develops drugs using PEGylation and polymer conjugates. The company has a pipeline which includes drug candidates in the pain, oncology, anti-infectives, hemophilia, and endocrine markets. Nektar’s approved product is Movantik, which is used for opiod-induced constipation.
The company’s other partners include Astrazeneca (AZN), Bayer (BAYN), Baxter (BAX), Ophthotech (OPHT), and Allergan (AGN).
Nektar has plenty of catalysts upcoming in the first half of 2014.
In the first quarter, Nektar is expecting to release Phase 3 topline data of Etirinotecan pegol NKTR-102 for Metastic Breast Cancer. This trial is termed their BEACON study.
Nektar Chief Medical Officer Ivan stated, “We were encouraged to find that the CTC sub-study confirmed the presence of several potential target-specific pharmacodynamic biomarkers, such as topoisomerase 1, in the patients enrolled in our study. The analysis from the BEACON CTC sub-study could help us better understand which additional patient populations would benefit from NKTR-102.”
In the first half of 2015, Nektar will announce Phase 3 INHALE 1 data of Inhaled Amikacin solution for Gram-Negative Pneumonia.
Mid-year, the company will also announce Phase 3 RESPIRE date of Cipro Dry Powder Inhaler for Non-cystic Fibrosis Bronchiectasis.
On January 13, Nektar will be presenting at the J.P. Morgan Healthcare conference in San Francisco. CEO Howard Robin will be speaking at 2 P.M. EST.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.